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Background: Respiratory syncytial virus (RSV) is a major 
cause of severe lower respiratory tract diseases in infancy 
and early childhood. Despite its importance as a pathogen, 
there is no licensed vaccine against RSV yet. The attachment 
glycoprotein (G) of RSV is a potentially important target for 
protective antiviral immune responses. Recombinant baculo-
virus has been recently emerged as a new vaccine vector, 
since it has intrinsic immunostimulatory properties and good 
bio-safety profile. Methods: We have constructed a recombi-
nant baculovirus-based RSV vaccine, Bac-RSV/G, display-
ing G glycoprotein, and evaluated immunogenicity and pro-
tective efficacy by intranasal immunization of BALB/c mice 
with Bac-RSV/G. Results: Bac-RSV/G efficiently provides 
protective immunity against RSV challenge. Strong serum 
IgG and mucosal IgA responses were induced by intranasal 
immunization with Bac-RSV/G. In addition to humoral im-
munity, G-specific Th17- as well as Th1-type T-cell responses 
were detected in the lungs of Bac-RSV/G-immune mice 
upon RSV challenge. Neither lung eosinophilia nor vac-
cine-induced weight loss was observed upon Bac-RSV/G 
immunization and subsequent RSV infection. Conclusion: 
Our data demonstrate that intranasal administration of bacu-
lovirus-based Bac-RSV/G vaccine is efficient for the in-
duction of protection against RSV and represents a promis-
ing prophylactic vaccination regimen.
[Immune Network 2012;12(1):8-17]
INTRODUCTION
Respiratory syncytial virus (RSV) is the most important viral 
pathogen of causing serious bronchiolitis and pneumonia in 
infants and young children worldwide. RSV is also receiving 
increasing recognition as an important cause of lower respira-
tory tract illness in immunocompromised patients, the young 
children, and the elderly (1-3). Despite the importance of RSV 
as a respiratory pathogen, there is no licensed vaccine cur-
rently  available  against  RSV  infection.
    In the 1960s, the immunization of children with formalin 
inactivated-RSV  (FI-RSV)  vaccine  not  only  failed  to  protect, 
but also yielded enhanced pulmonary disease in vaccinated 
infants  following  RSV  infection  (4,5).  Studies  with  BALB/c 
mice  have  become  a  useful  model  for  RSV  pathogenesis, 
since FI-RSV-enhanced disease is also observed in vaccinated 
BALB/c mice. It is likely that the augmented lung disease and 
the development of pulmonary eosinophilia are attributed to 
an  excessive  Th2  type  immune  response  (6).
  The RSV G protein is one of the major protective antigens 
and good inducer of strong serum and mucosal neutralizing 
antibody responses. It also has single immunodominant I-E
d 
epitope spanning RSV G amino acid 183 to 198 and largely 
induces a specific subset of CD4 T cells (7,8). Previously, we 
have reported that RSV G protein fragment (spanning amino 
acid residues  131-230)  delivered by recombinant adenoviral 
vector  successfully  elicited  long-term  protective  immunity Baculovirus-based Respiratory Syncytial Virus Vaccine
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Figure 1. Construction and characterization of Bac-RSV/G vaccine. (A)
The shuttle vector, pFastBac-RSV/G, was designed as shown in the 
diagram and constructed as described in the Materials and Methods. 
The vector was used to generate Bac-RSV/G recombinant baculovirus.
(B) The presence of the RSV G protein on Bac-RSV/G was confirmed
by western blotting. Viral particles were prepared as described in the
Materials and Methods, and subjected to western blotting with an RSV
G-specific monoclonal antibody.
against  RSV  infection  in  mice  (9).
    Baculoviruses are enveloped viruses possessing a rod-shap-
ed nucleocapsids in which double stranded circular DNA ge-
nome of 88-135Kbp is packaged (10). Baculoviruses are gen-
erally utilized as a vector for the high level production of re-
combinant proteins but they could be also employed in gene 
transfer to mammalian cells (11-13). Several research groups 
have demonstrated that vaccination with recombinant baculo-
virus  can  induce  high-level  humoral  and  cell-mediated  im-
munity against various antigens, suggesting that baculovirus 
could be used as a vaccine carrier (14,15). In addition, it has 
been reported that immunization with a recombinant baculo-
virus expressing the hemagglutinin gene of influenza virus eli-
cited a strong innate immune  response and  protected  mice 
against influenza virus challenge (16). Moreover, it is known 
that  there  is  no  baculovirus-specific  immunity  in  mammals 
that might  interfere  the action  of baculovirus-based  vaccine 
(17-19).
    In the present study, a recombinant baculovirus displaying 
the RSV G protein (Bac-RSV/G) was constructed. Our results 
clearly  show  that  strong  humoral  and  cellular  immune  re-
sponses  were  induced  by  intranasal  administration  of  Bac- 
RSV/G in a mouse model. Importantly, complete protection 
against  RSV  challenge  without  vaccine-induced  illness  was 
observed in Bac-RSV/G-immune mice, suggesting that vacci-
nation of Bac-RSV/G could be utilized as a prophylactic vacci-
nation  regimen  against  RSV  infection.
MATERIALS AND METHODS
Cells and preparation of RSV stock
Baculoviruses  were  propagated  in  Spodoptera  frugiperda 9  
(Sf9) insect cells using SF-900 serum-free medium (Invitrogen) 
at 27
oC. RSV A2 strain was propagated in HEp-2 cells (ATCC, 
Manassas, VA) in Dulbecco’s modified Eagle's medium (Life 
Technologies,  Gaithersburg,  MD)  supplemented  with  3% 
heat-inactivated  fetal  calf  serum,  2  mM  glutamine,  20  mM 
HEPES, nonessential amino acid, penicillin, and streptomycin 
and titrated for infectivity by plaque assay as described else-
where  (20).
Construction and production of recombinant bacul-
oviruses
The coding sequence of RSV G protein from RSV A2 strain 
was amplified from cDNA by PCR and cloned into the EcoR 
I and Xho I sites of pFastBac-1 vector (Fig. 1A). The recombi-
nant  baculovirus  was  subsequently  generated  by  using  the 
Bac-to-Bac
Ⓡ system (Invitrogen) following the manufacturer’s 
instructions.  The  recombinant  baculoviruses  were  purified 
from supernatants of infected Sf9 insect cells with 25% (w/v) 
s u c r o s e  i n  5  m M  N a C l ,  1 0  m M  E D T A  i n  a  S W 2 8  r o t o r  
(Beckman, USA) at 24,000 rpm for 75 min at 4
oC. The super-
natant  was  decanted,  and  the  pellet  was  resuspended  in 
phosphate-buffered  saline  (PBS)  and  centrifuged  for  4  h  at 
24,000 rpm, 4
oC. The viral pellet was resuspended in PBS and 
t i t r a t e d  b y  p l a q u e  a s s a y s  o n  S f 9  c e l l s .
Immunization and challenge
Female  BALB/c  mice  were  purchased  from  Charles  River 
Laboratories Inc. (Yokohama, Japan). Mice kept under specif-
ic-pathogen-free conditions. For immunization, 6- to 8-week- 
old mice were inoculated with baculoviruses via the intranasal 
(i.n.) route. For i.n. immunizations, mice were lightly anes-
thetized  by  ether/chloroform  inhalation,  and  2×10
8 P F U  o f 
Bac-RSV/G or Bac-control in a volume of 70μl was applied 
to the left nostril. Three to four weeks after second immuni-
zation, the mice were challenged i.n. with 1×10
6 PFU of live 
RSV A2 strain. All animal studies were performed according 
to  the  guidelines  of  our  Institutional  Animal  Care  and  Use 
Committee  (Approval  No. 2010-9-4).
ELISA
Blood was obtained from the retro-orbital plexus with a hep-
arinized capillary tube, collected in an Eppendorf tube, and Baculovirus-based Respiratory Syncytial Virus Vaccine
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centrifuged,  and  serum  was  stored  at  −20
oC .  R S V  G  p r o -
tein-specific  antibody  titers  in  immunized  mice  were  meas-
ured by a direct enzyme-linked immunosorbent assay (ELISA). 
Briefly, 96-well plates were coated overnight with 100μl/well 
of 0.5μg/ml of purified G protein fragment diluted in PBS 
and  then  blocked  with  PBS  containing  1%  skim  milk  and 
0.05% Tween-20 for 2 h. Sera were then added in serial dilu-
tions  and  incubated  for  2  h.  The  plates  were  washed  five 
times with PBS containing 0.05% Tween 20 and incubated for 
30 min with various dilutions of horseradish peroxidase-con-
jugated affinity-purified rabbit anti-mouse total IgG, secondary 
antibody (Zymed Laboratories, San Francisco, CA). The plates 
were washed five times and developed with 3,3',5,5'-tetrame-
thylbenzidine, and the reaction was stopped with 1 M H3PO4 
and analyzed at 450 nm with a Thermo ELISA plate reader. 
The wells receiving no serum were used to calculate cut-off 
values. 
Preparation of lung lymphocytes and flow cytome-
tric analysis
The  lungs  were  perfused  with  5  ml  of  PBS  containing  10 
U/ml heparin (Sigma-Aldrich, St. Louis, MO) through the right 
ventricle  using  a  syringe  fitted  with  25-gauge  needle.  The 
lungs were then removed and placed in RPMI medium sup-
plemented with glutamine, gentamicin, penicillin G, and 10% 
FBS  (HyClone,  Logan,  UT).  The  tissue  was  then  processed 
through a steel screen to obtain a single-cell suspension, and 
particulate matter was removed by passage through a 70-μm 
Falcon cell strainer (BD Labware, Franklin Lakes, NJ). Freshly 
explanted  BAL  fluid  or  lung  cells  were  purified  by  density 
gradient  centrifugation  and  stained  in  PBS-3%  FBS-0.09% 
NaN3  using  fluorochrome-conjugated  antibodies.  The  anti-
bodies used were anti-CD4 (clone RM4-5), anti-CD44 (clone 
IM7) or anti-CD43 (clone 1B11). Both antibodies were pur-
chased from BD PharMingen (San Diego, CA). After staining, 
cells were fixed in PBS-2% (wt/vol) paraformaldehyde, and 
events  were  acquired  using  a  FACSCalibur  flow  cytometer 
(BD Biosciences, San Diego, CA). To enumerate the number 
of  cytokine-producing  cells,  intracellular  cytokine  staining 
was performed as described elsewhere (21). In brief, 2×10
6 
freshly explanted lung lymphocytes were cultured in a culture 
tube. Cells were left untreated or stimulated with 10μM G 
(183-195) peptide (WAICKRIPNKKPG) and then incubated for 
5 h at 37
oC in 5% CO2. Brefeldin A (5μg/ml) (Sigma-Aldrich) 
was added for the duration of the culture period to facilitate 
intracellular  cytokine  accumulation.  Cells were  then  stained 
for surface markers, washed, fixed, permeabilized with fluo-
rescence-activated cell sorter buffer containing 0.5% saponin 
(Sigma-Aldrich, Seoul, Korea), and stained for cytokines. The 
antibodies  used  were  anti-IFN-γ  ( c l o n e  X M G 1 . 2 )  o r  a n -
ti-IL-17A (TC11-18H10.1). Dead cells were excluded on the 
basis of forward and side light scatter patterns. Data were col-
lected using CELLQuest software (BD Biosciences) and ana-
lyzed  with  CELLQuest  and  WinMDI  version  2.9  software 
(Scripps Research Institute, La Jolla, CA). Lung supernatants 
w e r e  a l s o  c o l l e c t e d  f o r  a n a l y s i s  w i t h  t h e  F l o w C y t o m i x  
(eBioscience), according to the protocol. Kits containing anti-
body beads (IL-4, IL-5, IL-6, IL-10, IL-13) were used to meas-
ure  cytokine  levels  in  each  of  the  samples.
Bronchoalveolar lavage (BAL) and eosinophil assay
At 5 days post-challenge, a subset of mice from each group 
was sacrificed and tracheotomy was performed. The lung air-
ways were washed with 0.8 ml of PBS containing 1% fetal 
bovine  serum  (FBS).  The  collected  bronchoalveolar  lavage 
(BAL)  cells  were  used  for  measuring  eosinophils.  Approxi-
mately 1×10
5 cells from BAL fluid were incubated for 15 min 
with anti-Fc receptor antibody (2.4G2) to prevent nonspecific 
binding. Next, cells were stained with specific antibodies at 
final  concentration  of  1μg/100μl  in  PBS-3%  FBS-0.09% 
NaN3. The antibodies used were PE-conjugated anti-Siglec-F 
(E50-2440),  APC-conjugated  anti-CD45  (30-F11),  and  FITC- 
c o n j u g a t e d  C D 1 1 c  ( H L 3 ) .  B o t h   antibodies  were  purchased 
from BD  PharMingen  (San  Diego, CA). After staining,  cells 
were fixed in PBS-2% (wt/vol) paraformaldehyde, and events 
were  acquired  using  a  FACSCalibur  flow  cytometer  (BD 
B i o s c i e n c e s ,  S a n  D i e g o ,  C A ) .
RSV titer in lung
Four or five days after RSV challenge, subsets of mice were 
euthanized and the lungs were removed into Eagle’s modified 
essential medium. The tissues were then processed through 
a steel screen to obtain a single-cell suspension, and partic-
ulate matter was removed by passage through a 70-μm cell 
strainer (BD Labware, Franklin Lakes, NJ). The supernatants 
were collected, and RSV titers in the supernatants were meas-
ured by standard plaque assay on subconfluent HEp-2 mono-
layers. The data are expressed as the PFU per gram of lung 
tissue.
Statistical analysis
Comparison  of  differences  was  conducted  by  using  an  un-Baculovirus-based Respiratory Syncytial Virus Vaccine
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Figure 2. Characterization of humoral immune responses induced by Bac-RSV/G vaccine. (A) BALB/c mice were immunized twice with 2×10
8
PFU of recombinant baculovirus (Bac-RSV/G or Bac-control) via intranasal route, and systemic anti-RSV IgG antibody titers were measured by
serum ELISA two weeks after boosting. (B) Secretory IgA titers were measured in the BAL fluid for each immune group five days after RSV 
challenge. The results represent Log2 endpoint values from four to five individual mice. Data are representative of at least three independent
experiments and data are average±SEM, n=4∼5 mice per group. N.D., not detected.
paired, two-tailed Student t test. The difference was consid-
ered  statistically  significant  when  the  p  value  was  ≤0.05.
RESULTS
Generation of recombinant baculovirus displaying RSV G
The  recombinant  baculovirus  expressing  RSV  G  coding  se-
quences  under  the  control  of  the  polyhedrin  promoter, 
B a c - R S V / G ,  w a s  g e n e r a t e d  u s i n g  B a c - t o - B a c  s y s t e m  w i t h  a  
pFastBac-1 plasmid as shown in Fig. 1A. To examine whether 
Bac-RSV/G express and display RSV G in the virus particle, 
western  blotting  analysis  was  performed  with  sucrose  gra-
dient-purified baculoviruses. Using the G-specific monoclonal 
antibody, specific bands of approximately 70 kDa to 90 kDa 
were detected in the purified Bac-RSV/G particles, but not in 
Bac-control virus particles (Fig. 1B). As a positive control, pu-
rified RSV particles produced in HEp-2 cells were used and 
slightly  higher  molecular  weight  bands  were  detected  (Fig. 
1 B).  Th e  si ze  d iff er en c e mi g ht  b e du e  to  d if fe re nt  pa tt e rn s 
of  glycosylation  between  insect  cells  and  human  cells.
Intranansal Bac-RSV/G immunization induces humoral 
immune responses
To investigate the immunogenicity of Bac-RSV/G, the groups 
of  mice  were  immunized  i.n.  with  Bac-RSV/G,  Bac-control, 
or PBS. RSV G-specific antibody levels in sera from the im-
mune mice at 2 weeks after priming and 2 weeks after boost-
ing  were  determined  by  ELISA.  The  specific  antibody  re-
sponses were barely detectable in all groups of mice at 14 
days after priming (data not shown). Following booster im-
munization, however, the mean titers of serum antibodies in-
creased  significantly  only  in  the  group  of  mice  immunized 
with  Bac-RSV/G  (Fig.  2A).
  Secretory IgA has been shown to directly mediate local im-
munity against aerial pathogens, implying an important role 
for antibody in protection in the upper respiratory tract (22). 
Thus,  for  an  effective  RSV  vaccine  development,  the  in-
duction  of  secretory  IgA  on  respiratory  mucosal  surface  is 
critical.  To  examine  whether  Bac-RSV/G  vaccination  elicits 
IgA response in the respiratory tract, bronchoalveolar lavage 
(BAL) was performed at day 5 after RSV challenge and levels 
of IgA were determined by RSV-specific ELISA. Each group 
of mice immunized with Bac-control or PBS did not exhibit 
any specific IgA response, whereas Bac-RSV/G-immune mice 
showed significantly enhanced level of specific IgA response 
(Fig. 2B). These results suggest that intranasal immunization 
of Bac-RSV/G effectively induce both RSV G-specific serum 
IgG  and  respiratory  IgA.
Intranasal Bac-RSV/G immunization induces G-specific 
Th1 and Th17 responses
Since the RSV G contains I-E
d-restricted CD4 T-cell epitope, 
we examined whether Bac-RSV/G immunization induces spe-
cific CD4 T cells or not. To this end, Bac-RSV/G, Bac-control, Baculovirus-based Respiratory Syncytial Virus Vaccine
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Figure 3. G-specific Th1-cell res-
ponse in Bac-RSV/G-immune mice. 
(A) Mice were i.n. immunized with 
Bac-RSV/G, Bac-control, or PBS and
challenged with RSV A2 four weeks
after boosting. Lung mononuclear 
cells were prepared from the lungs 
of the same group of mice (n=4∼5)
five days after challenge and stim-
ulated with G183-195 peptide (＋) or 
without peptide (−). Cells were 
stained for CD4, CD44, and IFN-γ, 
and analyzed by flow cytometry. 
Cells gated for CD4 are shown in 
each dot plot and the percentages 
represent the frequency of G-speci-
fic IFN-γ-positive cells. (B) Average
data represent mean±SD (n=5). 
The results are a representative of 
two independent experiments.
or PBS immune mice were challenged with RSV. CD4 T cell 
responses were evaluated at 5 days after challenge by meas-
uring the production of IFN-γ in lung lymphocytes that had 
been stimulated with I-E
d-restricted G (183-195) epitope pep-
tide ex vivo. As shown in Fig. 3, G-specific CD4＋IFN-γ＋ 
c e l l s  w e r e  d e t e c t e d  i n  t h e  l u n g s  o f  B a c - R S V / G - i m m u n i z e d  
group (∼2.5% of gated CD4 T cells on average), while few 
specific cells (＜0.2% of CD4 T cells) were observed in the 
lungs of Bac-control or PBS-immunized group. We next in-
vestigated whether immunization of Bac-RSV/G induces other 
CD4＋ T cell subset such as Th2 and Th17. Bac-RSV/G-vacci-
nated  mice  showed  increased  frequency  of  G-specific 
IL-17-producing CD4 T cells in the lungs after RSV challenge 
(∼3.7% of gated CD4 T cells on average; Fig. 4). However, 
the levels of Th2-type cytokines such as IL-4, IL-5, IL-10, and 
IL-13  measured  by  multiplex  antibody-based  bead  assays 
were not significantly different in the lungs from all groups 
of mice (Fig. 5). Together, these results indicated that mixed 
G-specific  Th1/Th17-cell  responses  were  induced  by  Bac- 
RSV/G  vaccination.
Protective efficacy of Bac-RSV/G vaccine against 
RSV challenge
To  determine  whether  Bac-RSV/G  has  protective  efficacy 
against RSV infection, mice were challenged with live RSV A2 
virus at four weeks after booster immunization. While there 
was active RSV replication in the lungs of the Bac-control or 
PBS  immune  mice,  immunization  of  Bac-RSV/G  prevented 
any detectable RSV replication in the lungs during the peak 
of infection (Fig. 6). Interestingly, immunization of Bac-con-
trol  resulted  in  partial  decrease  of  viral  replication  at  the 
peak. This might be due to nonspecific innate immunity in-
duced by baculovirus inoculation. It was previously reported 
that intranasal administration of wild-type baculovirus induces 
strong  innate  immune  responses  and  provides  protection 
against  lethal  challenge  of  influenza  virus  (16).Baculovirus-based Respiratory Syncytial Virus Vaccine
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Figure 6. Immune protection from respiratory RSV challenge by 
vaccination with Bac-RSV/G. Each group of immune mice was 
challenged with 1×10
6 PFU of RSV A2 at 4 weeks after immunization
and the level of viral replication in the lungs was determined by 
plaque assay at day 5. Results are expressed as the mean±SEM from
4 to 5 mice per group. The limit of detection is 200 PFU/g of lungs.
N.D., not detected.
Figure 5. Bac-RSV/G immunization does not induce Th2 type 
cytokines in the lung. Mice were immunized and challenged as in 
Fig. 3. Lungs from mice were harvested five days after RSV challenge,
and cytokine levels in the lung supernatant were assessed by 
multiplex antibody-based assay (FlowCytomix). Bars represent the 
mean of 4∼5 mice per group and data are a representative of two
independent experiments.
Figure 4. G-specific Th17-cell res-
ponse in Bac-RSV/G-immune mice. 
(A) Mice were immunized with 
Bac-RSV/G, Bac-control, or PBS i.n. 
and challenged with RSV four 
weeks after boosting. Lung mono-
nuclear cells were prepared from 
the lungs of the same group of mice 
(n=4∼5) five days after challenge 
and stimulated with G183-195 peptide
(＋) or without peptide (−). Cells 
were stained for CD4, CD43, and 
IL-17A, and analyzed by flow 
cytometry. Cells gated for CD4 are 
shown in each dot plot and the 
percentages represent the frequency
of G-specific IL-17A-positive cells. 
(B) Average data represent mean±
SD (n=5). The results are a repre-
sentative of two independent ex-
periments.Baculovirus-based Respiratory Syncytial Virus Vaccine
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Figure 7. Bac-RSV/G immunization promotes neither lung eosinophilia nor vaccine-enhanced illness. (A) Mice were immunized and challenged 
as in Fig. 3. BAL was performed five days after RSV challenge, and BAL cells were stained with antibodies to CD45, Siglec-F, and CD11c, 
and eosinophils were quantitated among CD45
＋-gated cells. Average percentages of Siglec-F＋CD11c-cells among total CD45
＋ cells represent
mean±SD (n=6). The results are a representative of three independent experiments. (B) The same group of immune mice were challenged with
RSV and then weighed each day. Results are expressed as the mean±SEM from 5 mice for each group. All data are representative of at least
two independent experiments.
Bac-RSV/G immunization do not promote vaccine- 
induced eosinophilia
It was reported that immunization with vaccinia virus express-
ing the entire RSV G glycoprotein results in pulmonary eosi-
nophilia following challenge with live RSV (6,23,24). These 
studies indicated that RSV G expressed vaccines have a possi-
bility for the development of pulmonary eosinophilia. To de-
termine  whether  the  intranasal  immunization  of  Bac-RSV/G 
potentiates eosinophilia, the levels of eosinophils in the BAL 
fluids of the immune mice were examined by flow cytometry 
5 days after RSV challenge using antibodies to Siglec-F, CD45, 
and  CD11c  as  described  previously  (25).  Bac-RSV/G-immu-
nized  mice  have  a  higher  frequency  of  CD11c-SiglecF＋ in 
the  BAL  as  compared  with  Bac-control  or  PBS  group  (Fig. 
7A, p＜0.05), but the level of eosinophil influx in Bac-RSV/G 
immune mice was relatively weak (∼2% of the total CD45＋ 
BAL  cells).  These  results  suggest  that  intranasal  Bac-RSV/G 
immunization  barely  increase  the  risk  of  vaccine-induced 
eosinophilia.
    To  evaluate  other  RSV-induced  pathology  by  Bac-RSV/G 
immunization, we monitored weight loss in all immune-mice 
after RSV challenge. Following infection with live RSV, there 
was  no  significant  weight  loss  in  Bac-RSV/G-immune  mice 
(Fig. 7B) and disease score (data not shown). Taken togeth-
er, these results suggest that intranasal Bac-RSV/G vaccination 
give rise to protective immunity in the absence of subsequent 
vaccine-enhanced  disease.
DISCUSSION
To develop a safe and effective RSV vaccine, many strategies 
and platforms have been applied in pre-clinical and clinical 
phases (26). Many RSV vaccine  candidates specifying target 
antigens employed two envelop proteins, G attachment pro-
tein and F fusion protein, because these antigens are known 
to  induce  protective  immunity  against  live  RSV  infection. 
However, in the BALB/c mouse model, immunization of G 
protein  expressed  from  recombinant  vaccinia  virus  elicited 
Th2-biased  responses,  which  was  responsible  for  the  vac-
cine-enhanced diseases (27). Thus, G protein has been falsely 
regarded  as  a  bad  target  antigen  for  a  long  time,  although 
it could induce strong neutralizing antibody responses upon 
immunization. Recently, it has been suggested that G protein 
itself is not the cause of vaccine-enhanced diseases and the 
proper balance between RSV-specific Th1 and Th2 responses 
is rather an important factor controlling both safety and effi-
cacy of G-targeted RSV vaccine. Using appropriate platforms 
and/or adjuvants, this balance could be achieved with G-tar-
geted vaccines. For example, we have recently demonstrated 
that  mucosal  immunization  of  recombinant  adenovirus  vac-Baculovirus-based Respiratory Syncytial Virus Vaccine
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cine expressing the  core domain of G successfully induced 
protective  immunity  without  vaccine-induced  diseases  (9).
    Baculovirus has recently been emerged as a new tool for 
vaccine vector development since it has many advantages as 
a vaccine platform (28-30). First, baculovirus, which has been 
used to overexpress recombinant  proteins in insect cells, is 
neither replication-competent nor pathogenic in mammalian 
cells, making it  safer vaccine  vector  than  other mammalian 
viral  vectors.  In  addition,  baculovirus-based  vaccines  pro-
duced in insect cells are not contaminated by LPS. Second, 
baculovirus-based vaccine possesses several advantages upon 
production,  such  as  easy  manipulation,  relatively  simple 
scale-up, and high titers (11,31). Thirdly, there is no pre-exist-
ing vector immunity against baculovirus in mammals, which 
enables baculovirus to escape vector neutralization by pre-ex-
isting immunity during in vivo delivery (19). Lastly, baculovi-
rus  has  the  ability  to  stimulate  strong  innate  immunity,  ex-
hibiting  strong  adjuvanticity  itself.  It  has  been  previously 
shown  that  inoculation  of  wild-type  baculovirus  alone  can 
stimulate the secretion of inflammatory cytokines from innate 
immune cells and confer protection from lethal virus infection 
in  mice  (16).  Consistent  with  this  report,  intranasal  in-
oculation  of  control  baculovirus  also  provided  partial  pro-
tection against live RSV challenge in our study (Fig. 6). The 
baculovirus-mediated stimulation of innate immunity might be 
associated with the induction of type I interferons, mediated 
by  both  TLR9-dependent  (32)  and  TLR9-independent  path-
ways (33). Thus, it becomes evident that baculovirus can act 
as a natural adjuvant by stimulating innate immunity and be 
u s e d  a s  a  s a f e  a n d  e f f e c t i v e  v a c c i n e  c a r r i e r .  
    Our data demonstrate that intranasal immunization of Bac- 
RSV/G  vaccine  induces  complete  protection  from  RSV  in-
fection, which is associated with enhanced Th1 and Th17 re-
sponses in the absence of significant Th2 responses. Although 
the  role of  Th1  or  CTL responses  to  RSV clearance is well 
delineated  (34),  the  role  of  Th17-mediated  responses  have 
not been fully elucidated in host defense against RSV. Th17 
cells, which are characterized by massive production of IL-17, 
are  thought  to  contribute  to  autoimmune  diseases  but  also 
play a crucial role in host defense against extracellular bac-
teria (35,36). In addition, Th17-associated effector molecules 
seem to be necessary and sufficient for protection against sev-
eral  viral  pathogens.  For  example,  recent  studies  have  re-
ported that Tc17 cells are potently cytolytic against vaccinia 
virus-infected cells (37,38). In these studies, both IL-17-pro-
ducing CD4＋ and CD8＋ T cells are necessary to confer pro-
tection against viral infections, exhibiting cytotoxic activity for 
clearance  of  vaccinia  virus-infected  cells.  Mice  immunized 
with a recombinant vaccinia virus expressing the G protein 
of RSV (vvG) exhibit pulmonary eosinophilia induced by Th2 
type cytokines after challenge RSV infection (6). Th2 type cy-
tokines are thought to promote eosinophil infiltration to the 
lungs  of  RSV-infected  mice  and  may  contribute  to  im-
munopathology  associated  with  vaccine-enhanced  diseases. 
Interestingly,  we  showed  that  the  levels  of  Th2-type  cyto-
kines,  such  as  IL-4,  IL-5,  IL-10,  or  IL-13,  were  very  low  in 
the  lungs  of  Bac-RSV/G-immune  mice  following  RSV  chal-
lenge, not significantly different to those in the PBS control 
group. Several evidences suggest that IL-17 negatively regu-
lates Th2 cytokine production (39,40). Thus, the induction of 
Th1/Th17 responses by Bac-RSV/G vaccination may have at-
tenuated  the  development  of  Th2  responses.  Furthermore, 
IL-17 may play certain roles in immune defense in the lungs, 
including augmentation of mucosal immunity by delivery of 
IgA and IgM into the airway lumen (41). Though the exact 
mechanism  by  which  the  Th17  responses  are  induced  by 
Bac-RSV/G vaccination is not clear, the G-specific Th17 re-
s p o n s e  m a y  b e  a s s o c i a t e d  w i t h  c l e a r a n c e  o f  R S V  f r o m  t h e  
lungs. Further studies will be needed to elucidate the exact 
role  of  Th17  immunity  in  RSV  infection.
    In conclusion, our present study demonstrates that baculo-
v i r u s  d i s p l a y i n g  R S V  G  p r o t e i n ,  B a c - R S V / G ,  i n d u c e s  a n t i -
gen-specific  humoral  and  cellular  immunity,  and  provides 
protection  against  RSV  challenge  without  vaccine-induced 
immunopathology. Thus, our study provides strong evidence 
that Bac-RSV/G vaccine could be further developed as a mu-
cosal  RSV  vaccine.
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